Precision Medicine World Conference
Duke University 2018

Meet with Q2 Solutions at PMWC Duke University

Duke University, Durham, NC | September 24, 2018 - September 25, 2018 | 08:00 - 17:00 Add to Calendar
Stay Informed Schedule a Meeting

About This Event

The Precision Medicine World Conference (PMWC) 2018 Duke, the 15th installment of the conference, will spotlight the latest advancements within biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

With laboratory services that span the development lifecycle and industry-leading scientists with extensive drug development experience, Q² Solutions can help you accelerate your path to precision medicine.

Plan to join our Ph.D., Principal Bioinformaticist and Scientific Advisor, Wendell Jones, on September 25th, at PMWC - Duke University in his session, “Immune Landscape Signatures: Characterization of Tumor Microenvironment (TME) and Response to Therapy”, where he will discuss the detection of Immune Landscape Signatures for characterization of tumor microenvironment and response to therapy.

Learn more about our precision medicine, companion diagnostics and genomics services, and register to attend on the event website.

We look forward to meeting you in Durham.

Related Services:

Register for Event


Wendell Jones, Ph.D.

Dr. Jones is currently Principal Bioinformaticist and Scientific Advisor at Q2 Solutions | EA Genomics. He conducts collaborative scientific research with clients in multiple areas, especially in oncology and immuno-oncology. His background includes leading the analysis, development and validation of the bioinformatic and computational systems that process complex genomic assays, including next generation sequencing assays, evaluating new and emerging genomic technologies, and developing bioinformatic implementation strategies. He consults with clients and provides thought leadership in industry and public consortiums involved in genomic science and measurement. Dr. Jones serves on the Board of Directors as Vice President of the new MAQC Society andis currently participating in the U.S. Food and Drug Administration (FDA)-led Sequencing Quality Control 2 (SEQC2) consortium which is investigating best-practice methods for variant calling in DNA sequencing studies.  Dr. Jones previously had leadership roles in the MAQC, MAQC-II, and SEQC consortiums.

Dr. Jones has over 15 years of experience in advanced genomic technologies and 20 years of experience in scientific and technology leadership positions, including serving as Vice President of Statistics and Bioinformatics at Expression Analysis, Inc (EA) and Chief Science Officer at Reliametrics, a Nortel Networks business unit. He has authored over 40 peer-reviewed publications and has presented at numerous scientific meetings and industry conferences and consortium workshops. Dr. Jones also serves as Adjunct Assistant Professor in the School of Medicine (Dept. of Pathology and Laboratory Medicine) at the University of North Carolina at Chapel Hill.

Updated as of September 2018.

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Read More